PH12013500051A1 - Crystalline form of a 3-phenoxymethylpyrrolidine compound - Google Patents
Crystalline form of a 3-phenoxymethylpyrrolidine compoundInfo
- Publication number
- PH12013500051A1 PH12013500051A1 PH1/2013/500051A PH12013500051A PH12013500051A1 PH 12013500051 A1 PH12013500051 A1 PH 12013500051A1 PH 12013500051 A PH12013500051 A PH 12013500051A PH 12013500051 A1 PH12013500051 A1 PH 12013500051A1
- Authority
- PH
- Philippines
- Prior art keywords
- crystalline form
- crystalline
- phenoxymethylpyrrolidine
- compound
- salt
- Prior art date
Links
- -1 3-phenoxymethylpyrrolidine compound Chemical class 0.000 title 1
- 150000003839 salts Chemical class 0.000 abstract 3
- LZLQEDMHCMNYFK-FZMZJTMJSA-N (3s)-3-[(1s)-1-(4-chlorophenoxy)-2-methylpropyl]pyrrolidine Chemical compound O([C@@H](C(C)C)[C@@H]1CNCC1)C1=CC=C(Cl)C=C1 LZLQEDMHCMNYFK-FZMZJTMJSA-N 0.000 abstract 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Psychology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Physical Education & Sports Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36277310P | 2010-07-09 | 2010-07-09 | |
| PCT/US2011/042518 WO2012006205A1 (en) | 2010-07-09 | 2011-06-30 | Crystalline form of a 3-phenoxymethylpyrrolidine compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12013500051A1 true PH12013500051A1 (en) | 2017-10-25 |
Family
ID=44510052
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH1/2013/500051A PH12013500051A1 (en) | 2010-07-09 | 2011-06-30 | Crystalline form of a 3-phenoxymethylpyrrolidine compound |
Country Status (20)
| Country | Link |
|---|---|
| US (4) | US8163794B2 (https=) |
| EP (1) | EP2590941A1 (https=) |
| JP (2) | JP5823512B2 (https=) |
| KR (1) | KR20130041916A (https=) |
| CN (1) | CN103038211B (https=) |
| AR (1) | AR083512A1 (https=) |
| AU (1) | AU2011276416B2 (https=) |
| BR (1) | BR112013000602A2 (https=) |
| CA (1) | CA2803090A1 (https=) |
| CL (1) | CL2013000085A1 (https=) |
| CO (1) | CO6680604A2 (https=) |
| IL (1) | IL223584A0 (https=) |
| MX (1) | MX2013000334A (https=) |
| NZ (1) | NZ605490A (https=) |
| PH (1) | PH12013500051A1 (https=) |
| RU (1) | RU2013105479A (https=) |
| SG (1) | SG186789A1 (https=) |
| TW (1) | TW201206882A (https=) |
| WO (1) | WO2012006205A1 (https=) |
| ZA (1) | ZA201300154B (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7994209B2 (en) * | 2009-07-13 | 2011-08-09 | Theravance, Inc. | 3-phenoxymethylpyrrolidine compounds |
| MX2013000334A (es) * | 2010-07-09 | 2013-02-26 | Theravance Inc | Forma cristalina de un compuesto 3-fenoximetilpirrolidina. |
| US12369722B2 (en) | 2018-05-23 | 2025-07-29 | L&P Property Management Company | Method of disassembling pocketed spring assembly with dimensionally stabilizing substrate |
| US11013340B2 (en) | 2018-05-23 | 2021-05-25 | L&P Property Management Company | Pocketed spring assembly having dimensionally stabilizing substrate |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020151712A1 (en) | 1999-09-14 | 2002-10-17 | Nan-Horng Lin | 3-pyrrolidinyloxy-3'-pyridyl ether compounds useful for controlling chemical synaptic transmission |
| DE60119047D1 (de) * | 2000-08-31 | 2006-06-01 | Pfizer | Phenoxyphenylheterozyklen als Serotonin-Wiederaufnahmehemmer |
| EP1725518A1 (en) * | 2004-03-05 | 2006-11-29 | Eli Lilly And Company | Pharmaceutical compounds |
| WO2008023258A1 (en) | 2006-08-23 | 2008-02-28 | Pfizer Products Inc. | Piperidine derivatives |
| CA2687721A1 (en) * | 2007-06-08 | 2008-12-18 | Arena Pharmaceuticals, Inc. | Crystalline forms of (r)-1-{2-[4'-(3-methoxy-propane-1-sulfonyl)-biphenyl-4-yl]-ethyl}-2-methyl-pyrrolidine, and compositions, and methods related thereto |
| ES2434250T3 (es) * | 2008-07-24 | 2013-12-16 | Theravance, Inc. | Compuestos de 3-(fenoxifenilmetil)pirrolidina |
| JP2012524098A (ja) * | 2009-04-15 | 2012-10-11 | セラヴァンス， インコーポレーテッド | ３−（フェノキシピロリジン−３−イル−メチル）ヘテロアリール、３−（フェニルピロリジン−３−イルメトキシ）ヘテロアリールおよび３−（ヘテロアリールピロリジン−３−イルメトキシ）ヘテロアリール化合物 |
| US7994209B2 (en) * | 2009-07-13 | 2011-08-09 | Theravance, Inc. | 3-phenoxymethylpyrrolidine compounds |
| MX2013000334A (es) * | 2010-07-09 | 2013-02-26 | Theravance Inc | Forma cristalina de un compuesto 3-fenoximetilpirrolidina. |
-
2011
- 2011-06-30 MX MX2013000334A patent/MX2013000334A/es active IP Right Grant
- 2011-06-30 SG SG2012094348A patent/SG186789A1/en unknown
- 2011-06-30 EP EP11738521.1A patent/EP2590941A1/en not_active Withdrawn
- 2011-06-30 WO PCT/US2011/042518 patent/WO2012006205A1/en not_active Ceased
- 2011-06-30 KR KR1020137001583A patent/KR20130041916A/ko not_active Withdrawn
- 2011-06-30 BR BR112013000602A patent/BR112013000602A2/pt not_active IP Right Cessation
- 2011-06-30 JP JP2013518688A patent/JP5823512B2/ja not_active Expired - Fee Related
- 2011-06-30 CA CA2803090A patent/CA2803090A1/en not_active Abandoned
- 2011-06-30 PH PH1/2013/500051A patent/PH12013500051A1/en unknown
- 2011-06-30 CN CN201180033815.4A patent/CN103038211B/zh not_active Expired - Fee Related
- 2011-06-30 AU AU2011276416A patent/AU2011276416B2/en not_active Ceased
- 2011-06-30 RU RU2013105479/04A patent/RU2013105479A/ru not_active Application Discontinuation
- 2011-06-30 US US13/173,204 patent/US8163794B2/en not_active Expired - Fee Related
- 2011-06-30 NZ NZ605490A patent/NZ605490A/en not_active IP Right Cessation
- 2011-07-07 AR ARP110102429A patent/AR083512A1/es unknown
- 2011-07-08 TW TW100124302A patent/TW201206882A/zh unknown
-
2012
- 2012-03-20 US US13/424,561 patent/US8383669B2/en not_active Expired - Fee Related
- 2012-12-12 IL IL223584A patent/IL223584A0/en unknown
- 2012-12-19 US US13/720,385 patent/US8791151B2/en not_active Expired - Fee Related
-
2013
- 2013-01-07 ZA ZA2013/00154A patent/ZA201300154B/en unknown
- 2013-01-09 CL CL2013000085A patent/CL2013000085A1/es unknown
- 2013-01-09 CO CO13003305A patent/CO6680604A2/es not_active Application Discontinuation
-
2014
- 2014-06-24 US US14/313,422 patent/US9120746B2/en not_active Expired - Fee Related
-
2015
- 2015-03-26 JP JP2015063809A patent/JP2015120752A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| AR083512A1 (es) | 2013-03-06 |
| CO6680604A2 (es) | 2013-05-31 |
| NZ605490A (en) | 2014-10-31 |
| JP2013532170A (ja) | 2013-08-15 |
| AU2011276416A1 (en) | 2013-02-14 |
| JP5823512B2 (ja) | 2015-11-25 |
| US20120178790A1 (en) | 2012-07-12 |
| US20140018407A1 (en) | 2014-01-16 |
| RU2013105479A (ru) | 2014-08-20 |
| TW201206882A (en) | 2012-02-16 |
| US8163794B2 (en) | 2012-04-24 |
| CN103038211B (zh) | 2015-04-15 |
| US9120746B2 (en) | 2015-09-01 |
| MX2013000334A (es) | 2013-02-26 |
| US8383669B2 (en) | 2013-02-26 |
| ZA201300154B (en) | 2013-09-25 |
| AU2011276416B2 (en) | 2015-04-02 |
| CA2803090A1 (en) | 2012-01-12 |
| US8791151B2 (en) | 2014-07-29 |
| CN103038211A (zh) | 2013-04-10 |
| US20120010265A1 (en) | 2012-01-12 |
| US20150080450A1 (en) | 2015-03-19 |
| WO2012006205A1 (en) | 2012-01-12 |
| EP2590941A1 (en) | 2013-05-15 |
| CL2013000085A1 (es) | 2013-03-15 |
| SG186789A1 (en) | 2013-02-28 |
| KR20130041916A (ko) | 2013-04-25 |
| JP2015120752A (ja) | 2015-07-02 |
| BR112013000602A2 (pt) | 2016-07-05 |
| IL223584A0 (en) | 2013-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2014001595A (es) | Compuestos de imidazol, composiciones y metodos de uso. | |
| PH12014500987A1 (en) | Neprilysin inhibitors | |
| PH12013501256A1 (en) | Compositions and methods for modulating fxr | |
| EP3715345A3 (en) | Preparation of lfa-1 inhibitor and polymorph thereof | |
| MY160392A (en) | Triptolide prodrugs | |
| IN2014KN00948A (https=) | ||
| MY170935A (en) | Neprilysin inhibitors | |
| EP4219465A3 (en) | Prmt5 inhibitors and uses thereof | |
| MY163394A (en) | Substituted aminobutyric derivates as neprilysin inhibitors | |
| AU2012214029A8 (en) | Rorgammat inhibitors | |
| SG191175A1 (en) | Neprilysin inhibitors | |
| PH12014502733A1 (en) | Neprilysin inhibitors | |
| MY172924A (en) | Neprilysin inhibitors | |
| MX2013011591A (es) | Métodos y composiciones para tratar enfermedades neurodegenerativas. | |
| EA201300250A1 (ru) | Оксадиазольные ингибиторы продуцирования лейкотриена | |
| MX2014004196A (es) | Citramida de rasagilina. | |
| WO2013109972A3 (en) | Therapeutic compounds | |
| IN2013DN02555A (https=) | ||
| PH12013500051A1 (en) | Crystalline form of a 3-phenoxymethylpyrrolidine compound | |
| MX2013006670A (es) | Derivado de 2-carboxamida-4-piperazinil-benzofurano. | |
| WO2012015687A3 (en) | Drug-ligand conjugates, synthesis thereof, and intermediates thereto | |
| PH12013500945A1 (en) | Crystalline forms of an alkoxymidazol-1-ylmethyl-biphenyl carboxylic acid | |
| HK1182713A (en) | Crystalline form of a 3-phenoxymethylpyrrolidine compound | |
| MX2013002656A (es) | Nuevo proceso. | |
| WO2012164055A3 (en) | New compounds, synthesis and use thereof in the treatment of pain |